hemantane and Substance-Withdrawal-Syndrome

hemantane has been researched along with Substance-Withdrawal-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for hemantane and Substance-Withdrawal-Syndrome

ArticleYear
Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model.
    Bulletin of experimental biology and medicine, 2019, Volume: 166, Issue:6

    Activities of noncompetitive NMDA receptor antagonists (aminoadamantane derivatives) were assessed in random-bred rats with modeled morphine withdrawal syndrome. A single intraperitoneal injection of hemantane (10 or 20 mg/kg) significantly and dose-dependently moderated some behavioral symptoms (teeth-chattering, ptosis, and vocalization) and reduced total score of morphine withdrawal syndrome. In morphine-abstinent rats, hemantane partially prevented the decrease in the thresholds of tactile sensitivity, but had no effect on locomotor activity and body weight loss. Under conditions of morphine withdrawal, intraperitoneal injection of amantadine (10 or 20 mg/kg) decreased motor activity and promoted body weight loss in parallel with the development of mechanical allodynia, but had no effect on the total withdrawal score. Comparison of aminoadamantane derivatives by behavioral and physiological parameters demonstrated the advantage of hemantane during morphine abstinence indicating the need of its study as a promising anti-addiction remedy.

    Topics: Adamantane; Amantadine; Animals; Gene Expression; Hyperalgesia; Injections, Intraperitoneal; Male; Morphine; Morphine Dependence; Motor Activity; Narcotic Antagonists; Rats; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Weight Loss

2019
Non-Competitive NMDA Receptor Antagonist Hemantane Reduces Ethanol Consumption in Long-Term Alcohol Experienced Rats.
    Bulletin of experimental biology and medicine, 2017, Volume: 164, Issue:2

    Activity of hemantane, an amino adamantane derivative, exhibiting the properties of lowaffinity non-competitive NMDA receptor antagonist, was evaluated in experimental in vivo models of alcoholism. Hemantane had no effects on the formation and manifestation of behavioral sensitization to ethanol in DBA/2 mice. Under conditions of free choice between 10% ethanol and water, hemantane (20 mg/kg/day for 14 days, intraperitoneally) significantly reduced the daily ethanol intake in random-bred male rats with formed alcohol motivation (>4 g/kg of ethanol). During modelling of withdrawal syndrome, hemantane administered intraperitoneally in doses of 5-20 mg/kg dose-dependently attenuated alcohol-deprivation effect after acute withdrawal with no effects on protracted abstinence. It was found that hemantane suppressed alcohol drinking behavior in long-term ethanol experienced rats and attenuated alcohol-seeking behavior after acute withdrawal.

    Topics: Adamantane; Alcoholism; Animals; Animals, Outbred Strains; Choice Behavior; Disease Models, Animal; Male; Mice; Mice, Inbred DBA; Motivation; Rats; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome

2017